Reinoud E Knops,Willeke van der Stuijt,Peter Paul H M Delnoy,Lucas V A Boersma,Juergen Kuschyk,Mikhael F El-Chami,Hendrik Bonnemeier,Elijah R Behr,Tom F Brouwer,Stefan Kääb,Suneet Mittal,Anne-Floor B E Quast,Lonneke Smeding,Jan G P Tijssen,Nick R Bijsterveld,Sergio Richter,Marc A Brouwer,Joris R de Groot,Kirsten M Kooiman,Pier D Lambiase,Petr Neuzil,Kevin Vernooy,Marco Alings,Timothy R Betts,Frank A L E Bracke,Martin C Burke,Jonas S S G de Jong,David J Wright,Ward P J Jansen,Zachary I Whinnet,Peter Nordbeck,Michael Knaut,Berit T Philbert,Jurren M van Opstal,Alexandru B Chicos,Cornelis P Allaart,Alida E Borger van der Burg,Jude F Clancy,Jose M Dizon,Marc A Miller,Dmitry Nemirovsky,Ralf Surber,Gaurav A Upadhyay,Raul Weiss,Anouk de Weger,Arthur A M Wilde,Louise R A Olde Nordkamp,PRAETORIAN Investigators‡,Jim W Cheung,Tjeerd Germans,Stefan Kaab,Francisco Leyva,Dominic A M J Theuns

Abstract:Background: The PRAETORIAN trial (A Prospective, Randomized Comparison of Subcutaneous and Transvenous Implantable Cardioverter Defibrillator Therapy) showed noninferiority of subcutaneous implantable cardioverter defibrillator (S-ICD) compared with transvenous implantable cardioverter defibrillator (TV-ICD) with regard to inappropriate shocks and complications. In contrast to TV-ICD, S-ICD cannot provide antitachycardia pacing for monomorphic ventricular tachycardia. This prespecified secondary analysis evaluates appropriate therapy and whether antitachycardia pacing reduces the number of appropriate shocks. Methods: The PRAETORIAN trial was an international, investigator-initiated randomized trial that included patients with an indication for implantable cardioverter defibrillator (ICD) therapy. Patients with previous ventricular tachycardia <170 bpm or refractory recurrent monomorphic ventricular tachycardia were excluded. In 39 centers, 849 patients were randomized to receive an S-ICD (n=426) or TV-ICD (n=423) and were followed for a median of 49.1 months. ICD programming was mandated by protocol. Appropriate ICD therapy was defined as therapy for ventricular arrhythmias. Arrhythmias were classified as discrete episodes and storm episodes (≥3 episodes within 24 hours). Analyses were performed in the modified intention-to-treat population. Results: In the S-ICD group, 86 of 426 patients received appropriate therapy, versus 78 of 423 patients in the TV-ICD group, during a median follow-up of 52 months (48-month Kaplan-Meier estimates 19.4% and 17.5%; P=0.45). In the S-ICD group, 83 patients received at least 1 shock, versus 57 patients in the TV-ICD group (48-month Kaplan-Meier estimates 19.2% and 11.5%; P=0.02). Patients in the S-ICD group had a total of 254 shocks, compared with 228 shocks in the TV-ICD group (P=0.68). First shock efficacy was 93.8% in the S-ICD group and 91.6% in the TV-ICD group (P=0.40). The first antitachycardia pacing attempt successfully terminated 46% of all monomorphic ventricular tachycardias, but accelerated the arrhythmia in 9.4%. Ten patients with S-ICD experienced 13 electrical storms, versus 18 patients with TV-ICD with 19 electrical storms. Patients with appropriate therapy had an almost 2-fold increased relative risk of electrical storms in the TV-ICD group compared with the S-ICD group (P=0.05). Conclusions: In this trial, no difference was observed in shock efficacy of S-ICD compared with TV-ICD. Although patients in the S-ICD group were more likely to receive an ICD shock, the total number of appropriate shocks was not different between the 2 groups. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT01296022.

Present criteria for prophylactic ICD implantation: Insights from the EU-CERT-ICD (Comparative Effectiveness Research to Assess the Use of Primary ProphylacTic Implantable Cardioverter Defibrillators in EUrope) project

Abstract 13047: Clinical Risk Stratification for Primary Prevention Implantable Cardioverter Defibrillators (Icds)

Implantable cardioverter defibrillator therapy for primary prevention of sudden cardiac death: a single center experience

Abstract 12506: Implantable Cardioverter Defibrillators for Primary Prevention in Patients With Ischemic and Non Ischemic Cardiomyopathy: A Meta-Analysis of 15 Randomized Controlled Trial

Dutch outcome in implantable cardioverter-defibrillator therapy (DO-IT): registry design and baseline characteristics of a prospective observational cohort study to predict appropriate indication for implantable cardioverter-defibrillator

Prophylactic ICD implantation for primary prevention of sudden cardiac death

Implantable Cardioverter Defibrillators for Sudden Cardiac Death Prevention in China: A Regional Analysis from the Improve SCA Clinical Trial

Comparison of the Benefit of Primary Prevention Implantable Cardioverter-Defibrillator Therapy in Ischemic Versus Nonischemic Dilated Cardiomyopathy

Perioperative Safety and Early Patient and Device Outcomes Among Subcutaneous Versus Transvenous Implantable Cardioverter Defibrillator Implantations : A Randomized, Multicenter Trial

Efficacy and safety of implantable cardioverter-defibrillator implantation in the elderly-The I-70 Study: A randomized clinical trial

Wearable defibrillator to improve accuracy in selecting candidates to implantable defibrillator: A real-world experience

First-Line Catheter Ablation of Monomorphic Ventricular Tachycardia in Cardiomyopathy Concurrent With Defibrillator Implantation: The PAUSE-SCD Randomized Trial

Decision-making regarding subcutaneous implantable cardioverter defibrillator as primary prevention in patients with low ejection fraction

Feasibility of entirely subcutaneous ICD™ systems in patients with coronary artery disease

The extravascular implantable cardioverter-defibrillator: The pivotal study plan

Primary Prevention of Sudden Cardiac Death Using Implantable Cardioverter Defibrillators

Implantable cardioverter defibrillator use in arrhythmogenic right ventricular cardiomyopathy in North America and Europe

Efficacy and Safety of Appropriate Shocks and Antitachycardia Pacing in Transvenous and Subcutaneous Implantable Defibrillators: Analysis of All Appropriate Therapy in the PRAETORIAN Trial

Association between implanted cardioverter-defibrillators and mortality for patients with left ventricular ejection fraction between 30% and 35

Implantable cardioverter defibrillator is primary prophylactic therapy for sudden cardiac death in patients with heart failure

Time dependence of risks and benefits in pediatric primary prevention implantable cardioverter-defibrillator therapy